Abstract: This invention relates to the field of authentication of coating compositions such as varnishes, inks and paints, and it is particularly useful in the field of authentication of such coating compositions when applied to substrates like banknotes or other valuable documents. It is particularly directed to a marked coating composition. e.g. an ink, that is marked with a marker (taggant) such as to allow for its authentication, and a method for authenticating such a marked coating composition. The marking is achieved by covalently binding a taggant to a coating composition component. e.g. such used for security documents. The taggant, which is not extractable through usual chemical treatments like washing methods or the use of solvents, can be detected and identified upon thermally induced chemical fragmentation with a PY-GC-MS apparatus. The marked ink or the marked substrate is thus authenticated as belonging to a particularly marked ink, varnish or batch.

Abstract: The invention relates to the use of a composition of A) at least one quaternary ammonia compound comprising at least one organic radical bonded to the ammonia nitrogen atom and optionally comprising heteroatoms and having 1 to 36 carbon atoms, and B) at least one amine alkoxylate ester of formula (1) or a salt thereof, where A, B are, independently of each other, a C2- through C5-alkylene radical R1, a C8- through C24-alkyl radical or alkenyl radical R2, R3, R4 independent of each other, H, or a C8- through C24-acyl radical, with the stipulation that at least one of the radicals R2, R3 or R4 stands for a C8- through C24-acyl radical, and x, y, z, independently of each other, stand for a whole number from 0 through 50, with the stipulation that x+y+z is a whole number from 1 through 100, in quantities of 10 through 5000 g/tonne of ore as a collector in silicate floation.

Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

Abstract: A poly(nitrogen/amine) derivative of a natural wax of formula I, and ophthalmic compositions and contact lens care solutions that contain the poly(nitrogen/amine) derivative of a natural wax of formula I. The invention is also directed to a method of treating a patient with dry eyes, the method comprising instructing a patient to administer one or more eye drops of the ophthalmic composition that includes a poly(nitrogen/amine) derivative of a natural wax of formula I.

Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.

Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

Abstract: An additive compound comprising a derivative of particular fatty acids and polyamines has been found to be friction reducing, and particularly readily miscible in fuels and lubricants. The fatty acid has more than 12 carbon atoms and at least one carboxylic group. The polyamine residue has more than two nitrogen atoms. The mole ratio of the carboxylic groups to nitrogen atoms used to form the compound is greater than 0.8 carboxylic groups per 1 nitrogen atom.

Abstract: A composition comprising 40 to 90 wt % of at least one fatty amine carboxylate salt, water, and the carboxylic acid corresponding to said carboxylate is provided. In the composition, the weight:weight ratio of carboxylic acid:water is in the range of from 20:1 to 1:1. The inventive compositions have a pour point at a temperature of below 30° C.

Abstract: This invention relates to functionalized polymers derived from functionalized monomers. The functionalized polymer may be reacted with an enophilic reagent (e.g., maleic anhydride) to form an enophilic reagent modified functionalized polymer. The functionalized polymer may be further reacted with one or more additional reagents, e.g., an oxygen-containing reagent (e.g., alcohol, polyol), a nitrogen-containing reagent (e.g., amine, polyamine, aminoalcohol), a metal, a metal compound, or a mixture of two or more thereof. The invention relates to lubricants, functional fluids, fuels, dispersants, detergents and polymer compositions.

Abstract: This invention relates to a composition, comprising: an unsaturated functionalized monomer of from about 5 to about 30 carbon atoms, which is: (a) polymerized to form a functionalized polymer; (b) copolymerized with a comonomer to form a functionalized copolymer; or (c) reacted with an enophilic reagent to form a polyfunctionalized monomer. The polyfunctionalized monomer may be polymerized to form a polyfunctionalized polymer which may be further reacted with one or more additional reagents. The invention relates to lubricants, functional fluids, fuels, dispersants, detergents and polymeric resins.

Abstract: The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

Abstract: Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.

Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.

Abstract: A composition comprising 40 to 90 wt % of at least one fatty amine carboxylate salt, water, and the carboxylic acid corresponding to said carboxylate is provided. In the composition, the weight:weight ratio of carboxylic acid:water is in the range of from 20:1 to 1:1. The inventive compositions have a pour point at a temperature of below 30° C.

Abstract: The present invention provides unbranched aliphatic polyamines for use in therapy, particularly for use in the treatment of psoriasis and compositions containing polyamines.

Abstract: The present invention describes compounds produced from a Creatinol molecule and a fatty acid molecule. The compounds being in the form of Creatinol-fatty compounds bound by an ester linkage, or mixtures thereof produced by reacting Creatinol or derivatives of Creatinol with an appropriate fatty acid in the presence of dichloromethane and an acid catalyst. The administration of such molecules provides supplemental Creatinol with enhanced bioavailability and having additional benefits conferred by the specific fatty acid.

Abstract: Disclosed are polyol esters comprising a polyol having at least one hydroxyl group esterified to at least one compound having a carboxyl group. Methods of making the polyol ester compounds are also disclosed. The invention also relates to feed compositions comprising polyol ester compounds.

Abstract: A solid phase synthetic method for preparing arylretinamides is provided. The method comprises reacting hexachloroacetone with a solvent-suspended resin-bound triphenylphosphine to provide a suspension comprising an activated chlorinating reagent; reacting retinoic acid with the activated chlorinating reagent to provide retinoyl chloride; adding pyridine and a select arylamine to the resulting mixture; and stirring the resulting mixture for a time and at a temperature sufficient for the select arylamine to react with the retinoyl chloride and provide the arylretinamide. Also provided, are select arylretinamides that can be prepared by the present method, and methods of using such arylretinamides to induce apoptosis in cancer cells.

Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.

Abstract: The present invention contains novel compounds useful as nitric oxide synthase inhibitors.

Abstract: This invention relates to a leather that contains scent-containing microcapsules in its cross section, wherein the walls of the microcapsules comprise reaction products of guanidine compounds and polyisocyanates.

Abstract: The invention discloses stable diesters of chelating agents of divalent metal ions, processes for their preparation and pharmaceutical compositions thereof. Most preferred compounds according to the present invention are stable lipophilic diesters comprising a covalent conjugate of a BAPTA and a pharmaceutically acceptable alcohol. The diesters are useful in a method for treating a condition or disease related to an excess of divalent metal ions, and in particular for the treatment of a condition or disease related to elevated levels of intracellular calcium ions, such as in brain or cardiac ischemia, stroke, epilepsy, Alzheimer's disease or cardiac arrhythmia and in open heart surgery.

Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a mammal related to supranormal intracellular enzyme activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound is activated selectively within cells having such supranormal intracellular enzyme activity.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non-steroidal anti-infiammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.

Abstract: The compound 7,10,12-trihydroxy-8(E)-octadecenoic acid (TOD) has been produced by bioconversion of ricinoleic acid by Pseudomonas aeruginosa PR3. TOD and derivatives thereof are useful for controlling biological organisms, such as fungi and insects.

Abstract: The present invention relates to new lipopolyamines (including salts thereof) characterised by a symmetrical, highly flexible lipophilic moiety having buffering capacity at physiological pH, and to the use thereof for the in vivo or in vitro introduction of biologically active materials, such as, for example, DNA, RNA, ribozymes, antisense DNA, PNA, peptides and proteins, into eukaryotic cells.

Abstract: Water-soluble dodecandioates wherein the cationic moiety is selected from the group comprising the cations of basic aminoacids (e.g. lysine) and choline and orally or parenterally administrable compositions containing same, are disclosed.

Abstract: An additive for enhancing the performance of industrial pigments. The additive improves dispersibility and is the reaction product of an amine, a fatty amine, and a polybasic acid.

Abstract: Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, staight or branched alkanoyl having 2-26 carbon atoms, optionally &ohgr;-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

Abstract: Amine containing compounds and their use in the generation of cytofectin:polynucleotide complexes for transfection of cells, formulations, counterions, and reaction conditions for maximizing the transfection include using cationic amine compounds that have the general structure: ##STR1## wherein R.sub.4 and R.sub.5 are a pair of same or different lipoyl moieties selected from a group consisting of an alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, or alkynoyl groups and for R.sub.1, R.sub.2, and R.sub.3 at least two are hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl groups or at least one amine bonded halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group or a mixture of at least one halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group and at least one hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl group, and X.sup.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non.about.steroidal anti.about.inflammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.

Abstract: According to the invention, an improved class of amphoteric surfactants having improved surfactant properties charaterized as mild and environmentally benign has been provided comprising a compound of the general formula: ##STR1## wherein R independently represents a C.sub.5 to C.sub.22 alkyl or acyl (RCO--); R.sub.1 represents a C.sub.1 to C.sub.6 alkyl; R.sub.2 independently represents --O--; R.sub.3 represents a C.sub.2 to C.sub.20 alkylene, arylene, or alkylarylene and M is Na, K, NH.sub.4, an organic base, or hydrogen.In addition to the novel compounds per se, the invention also provides new methods for the preparation of the amphoteric gemini surfactants as well as improved synergistic compositions that are obtained when the amphoteric geminis are blended with other surfactants.

Abstract: Novel derivatives of fatty acid analogs that have from one to three heteroatoms in the fatty acid moiety which can be oxygen, sulfur or nitrogen, are disclosed in which the carboxy-terminus has been modified to form various amides, esters, ketones, alcohols, alcohol esters and nitriles thereof. These compounds are useful as substrates for N-myristoyltransferase (NMT) and/or its acyl coenzyme, and as anti-viral and anti-fungal agents or pro-drugs of such agents. Illustrative of the disclosed compounds are fatty acid amino acid analogs of the structure ##STR1## in which X is the ethyl or t-butyl ester of an amino acid such as Gly, L-Ala, L-Ile, L-Phe, L-Try, L-Thr, or an amide such as NHCH.sub.2 C.sub.6 H.sub.5 or NH(CH.sub.2).sub.2 C.sub.6 H.sub.5.

Abstract: Diquaternary ammonium esters useful as bleach activators are disclosed as are bleach compositions comprising such an ester and peroxygen compound yield peroxide in solution.

Abstract: Disclosed are bleaching compositions comprising diquaternary ammonium esters which are useful as bleach activators with a peroxygen compound to yield peroxide in solution.

Abstract: Aromatic acid-derived lipophilic polyhalogenated compounds are provided for use as contrast agents in diagnostic imaging or as therapeutic agents. These compounds are particularly useful when incorporated into an oil-in-water emulsion for tissue-specific delivery to the liver. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm and having a composition simulating naturally-occuring chylomicron remnants.

Abstract: The invention relates to caged compounds for the study of biological processes, where the caged compound has a photoremoveable .alpha.-carboxy-substituted o-nitrobenzyl group. Covalent attachment of the substituted o-nitrobenzyl to a parent compound yields a caged compound with biological and/or physical properties that are significantly altered from the original properties of the parent compound. Illumination of the caged compounds to cleave the photoremoveable group yields the parent compound with its original properties restored.

Abstract: The invention relates to cyclopentane ether derivatives of Formula I ##STR1## their salts with physiologically compatible bases, as well as the .alpha.-, .beta.- or .gamma.-cyclodextrin clathrates, and also the liposome-encapsulated compounds of Formula I, processes for their production, and their pharmaceutical usage.

Abstract: Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, straight or branched alkanoyl having 2-26 carbon atoms, optionally .omega.-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

Abstract: Diquaternary ammonium esters useful as bleach activators are disclosed, as are bleach compositions comprising such an ester and a peroxygen compound which yields peroxide in solution.

Abstract: A process is reported for the preparation of bis(amidocarboxylic acid) involving reacting an ester with an aminocarboxylate compound, the latter being formed from lactams or aminocarboxylic acids and salts thereof. The ester and aminocarboxylate compound are present in a weight ratio of about 1:1 to about 1:4, and reaction is conducted in a mono- or polyhydric alcohol solvent.